How much does capmatinib cost from the second factory in Laos?

Capmatinib (Capmatinib) is a targeted therapy drug developed by Novartis (Novartis Pharmaceuticals). It is mainly used for the treatment of non-small cell lung cancer (NSCLC). The development of this drug aims to target the overexpression or genetic mutation of MET (tyrosine kinase) in patients with lung cancer. By inhibiting the activity of MET kinase, it interferes with abnormal cell signaling, thereby preventing the growth and spread of cancer cells.

Capmatinib is not yet available in China, so patients cannot purchase it domestically yet and need to purchase it through overseas channels. Currently, there are Hong Kong version of original drugs and foreign original drugs and generic drugs. The price of Hong Kong version of original drugs is about 35,000 yuan. The overseas original drugs are mainly European version of original drugs, and the price is more than 50,000 yuan, so original drugs are still relatively expensive.

The generic drugs on the market abroad are much cheaper, mainly Lao generic drugs.Currently there is no capmatinib produced by the second factory in Laos. It is mainly produced by Lucius, Daxiong, United, Element and other pharmaceutical companies. The price is around 3,000 to 4,000, and the ingredients of the original drug and the generic drug are basically the same.

METis a protein involved in cell growth, differentiation and migration, and in some cancers, abnormal activation of the MET pathway may lead to the development of tumors. The mechanism of action of capmatinib is to selectively block MET kinase, thereby interfering with the survival signals of lung cancer cells, providing patients with a more personalized and targeted treatment option.

Capmatinib is usually given to patients in the form of an oral drug, which has a certain degree of bioavailability and is convenient for patients to treat at home. The drug has shown promising efficacy in several clinical trials, particularly in patients with MET-driven non-small cell lung cancer, resulting in significant clinical benefit.